Vinay Mehindru, MD, MBA Appointed to RetinalGenix Technologies Inc. Board of Directors
July 26, 2022 06:15 ET
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- RetinalGenix™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), announced today the appointment of Vinay Mehindru, MD, MBA to the...
Sunglasses Global Market Report 2022-2026: Featuring Key Players Fielmann AG, Marcolin, De Rigo Vision, Stylrite Optical & Eyevan
July 12, 2022 07:38 ET
|
Research and Markets
Dublin, July 12, 2022 (GLOBE NEWSWIRE) -- The "Sunglasses Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.The global sunglasses market is expected to grow from...
RetinalGeniX Technologies, Inc. Acquires DNA/GPS Inc.
July 06, 2022 08:00 ET
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), announced today the acquisition of DNA/GPS Inc.,...
Graybug to Present at the 2022 OIS Retina Innovation Summit
July 06, 2022 07:15 ET
|
Graybug Vision, Inc.
BALTIMORE, July 06, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Efficacy of Notal Vision Home OCT demonstrated by a series of scientific and clinical work
June 29, 2022 08:00 ET
|
Notal Vision
Manassas, VA, June 29, 2022 (GLOBE NEWSWIRE) -- Notal Vision, Inc. reported today that numerous scientific and clinical publications and presentations prove the feasibility and efficacy of their...
CareMetx and USRetina Partner to Better Support Ophthalmology and Retina Patients
June 28, 2022 15:35 ET
|
CareMetx, LLC
Bethesda, MD, June 28, 2022 (GLOBE NEWSWIRE) -- CareMetx, a leading technology-enabled hub services company focused on improving patient access to specialty medications, and USRetina, the largest...
Graybug Announces Review of Strategic Alternatives
June 28, 2022 07:15 ET
|
Graybug Vision, Inc.
BALTIMORE, June 28, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug Vision Reports First Quarter 2022 Financial Results and Recent Corporate Developments
May 10, 2022 16:05 ET
|
Graybug Vision, Inc.
BALTIMORE, May 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today...
Graybug Vision Appoints Dirk Sauer to Board of Directors
April 13, 2022 16:05 ET
|
Graybug Vision, Inc.
BALTIMORE, April 13, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug Announces Pipeline Expansion, Current Cash Expected to Deliver Three Clinical Readouts in 2023
March 30, 2022 07:15 ET
|
Graybug Vision, Inc.
Phase 2 trial with optimized formulation in wet AMD expected to start in fourth quarter of 2022Phase 1 trial in glaucoma expected to commence in first quarter of 2023Acquired corneal gene therapy...